# A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer

Source: https://onco.cc/trials/nct07102381/  
OnCo record `nct07102381` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Zanidatamab, Paclitaxel / nab-paclitaxel, Docetaxel in her2-positive breast cancer, run by Jazz Pharmaceuticals, now recruiting.

## Summary

A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer is a phase 2 interventional study registered as NCT07102381 by Jazz Pharmaceuticals, with 125 participants planned, started 2025-09-24 and due to reach its primary completion in 2028-01-01. Interventions recorded: Zanidatamab, Paclitaxel, Docetaxel, Carboplatin, Trastuzumab. Conditions listed: HER2-positive Breast Cancer, Breast Cancer. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT07102381
- Phase: 2
- Setting: A Phase 2, Randomized, Multicenter, Open-label Neoadjuvant Study Evaluating Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer
- Sponsor: Jazz Pharmaceuticals
- Enrolled: 125

## Sources

- ClinicalTrials.gov NCT07102381: https://clinicaltrials.gov/study/NCT07102381

## Connected records

- cancers: [HER2-positive breast cancer](https://onco.cc/cancers/breast-her2-positive/)
- drugs: [Carboplatin](https://onco.cc/drugs/carboplatin/), [Docetaxel](https://onco.cc/drugs/docetaxel/), [Paclitaxel / nab-paclitaxel](https://onco.cc/drugs/paclitaxel/), [Pertuzumab](https://onco.cc/drugs/pertuzumab/), [Trastuzumab](https://onco.cc/drugs/trastuzumab/), [Zanidatamab](https://onco.cc/drugs/zanidatamab/)
- companies: [Jazz Pharmaceuticals](https://onco.cc/companies/jazz/)

---
JSON: https://onco.cc/api/v1/entities/nct07102381.json